Taizhou Hospital of Zhejiang Province Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial
2011
NCT02188615
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Chengchu Zhu | Taizhou Hospital of Zhejiang Province | TAIZHOU HOSPITAL OF ZHEJIANG PROVINCE | Taizhou Municipal Hospital

Active Ingredients

Drugs in Phase 3 Trials (2)

borneol (1 trial)

epoetin (Epogen) (1 trial)

Drugs in Phase 2 Trials (3)

cisplatin (platinol) (1 trial)

imatinib (gleevec) (1 trial)

sintilimab (2 trials)

Drugs in Other Trials (2)

acetylsalicylic acid (aspirin) (1 trial)

rivaroxaban (xarelto) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Aortic Dissection (Phase 2)

Carcinoma (Phase 2)

Esophageal Neoplasms (Phase 2)

Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial APIs: 7